Citigroup’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-439
Closed -$23K 7766
2020
Q3
$23K Sell
439
-1,504
-77% -$92.8K ﹤0.01% 6114
2020
Q2
$119K Buy
1,943
+105
+6% +$6.07K ﹤0.01% 5437
2020
Q1
$104K Buy
1,838
+513
+39% +$29.2K ﹤0.01% 5314
2019
Q4
$75K Buy
1,325
+522
+65% +$27.7K ﹤0.01% 6001
2019
Q3
$43K Sell
803
-905
-53% -$52.7K ﹤0.01% 6224
2019
Q2
$102K Buy
1,708
+244
+17% +$15.4K ﹤0.01% 5860
2019
Q1
$92K Buy
1,464
+75
+5% +$4.96K ﹤0.01% 5830
2018
Q4
$84K Sell
1,389
-107
-7% -$6.39K ﹤0.01% 5808
2018
Q3
$87K Buy
1,496
+483
+48% +$24.6K ﹤0.01% 6038
2018
Q2
$45K Sell
1,013
-1,119
-52% -$48.1K ﹤0.01% 6371
2018
Q1
$94K Sell
2,132
-80
-4% -$3.36K ﹤0.01% 5677
2017
Q4
$96K Sell
2,212
-1,061
-32% -$47.7K ﹤0.01% 5681
2017
Q3
$152K Buy
3,273
+2,206
+207% +$106K ﹤0.01% 5218
2017
Q2
$53K Buy
1,067
+119
+13% +$6.23K ﹤0.01% 5750
2017
Q1
$52K Sell
948
-4,493
-83% -$238K ﹤0.01% 5674
2016
Q4
$303K Buy
5,441
+1,977
+57% +$95K ﹤0.01% 4922
2016
Q3
$158K Buy
3,464
+2,053
+145% +$82.5K ﹤0.01% 4855
2016
Q2
$56K Sell
1,411
-2,715
-66% -$99.4K ﹤0.01% 5504
2016
Q1
$143K Buy
4,126
+2,025
+96% +$74.3K ﹤0.01% 5400
2015
Q4
$90K Buy
+2,101
New +$105K ﹤0.01% 5458
2015
Q3
Sell
-1,839
Closed -$95K 7907
2015
Q2
$95K Buy
1,839
+1,630
+780% +$69.5K ﹤0.01% 5048
2015
Q1
$8K Sell
209
-11,217
-98% -$440K ﹤0.01% 6570
2014
Q4
$441K Buy
11,426
+11,298
+8,827% +$431K ﹤0.01% 4000
2014
Q3
$5K Buy
128
+72
+129% +$2.11K ﹤0.01% 6590
2014
Q2
$2K Buy
+56
New +$1.46K ﹤0.01% 6810
2013
Q4
Sell
-98
Closed -$2K 7220
2013
Q3
$2K Buy
+98
New +$1.74K ﹤0.01% 6613

Other funds holding BSTC

Citigroup's BSTC Position: Q4 2020 in Review

Citigroup sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 439 shares — an estimated $23K sold.

Citigroup first reported a position in BSTC in Q3 2013 and held it in 26 quarters. The position peaked at $441K in Q4 2014. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

  • Citigroup reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
  • Citigroup sold 439 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $23K.
  • Citigroup first reported a position in BioSpecifics Technologies Corp. in Q3 2013 and held it in 26 quarters.
  • Citigroup's BioSpecifics Technologies Corp. position peaked at $441K in Q4 2014.
  • 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on Citigroup's 13F filing for Q4 2020, filed 11 Feb 2021.